Press Releases

New Clinical Data Highlighting Safety and Efficacy of EndoBarrier® Therapy Presented at the 19th World Congress of International Federation for the Surgery of Obesity and Metabolic Disorders

Data Further Demonstrate the Utility of EndoBarrier Therapy in the Treatment of Patients with Type 2 Diabetes and Obesity MONTREAL, Canada, LEXINGTON, United States and SYDNEY, Australia – 29 August 2014 – GI Dynamics, Inc. (ASX: GID), a medical device company developing innovative treatments for...

read more

Appendix 4C Quarterly Report Quarter ended 30 June 2014

GI Dynamics to Hold Briefing Call and Webcast on Financial Results for Second Quarter 2014 on Monday, 4 August 2014 at 6 p.m. U.S. EDT  / Tuesday, 5 August 2014 at 8 a.m. AEST     LEXINGTON, Massachusetts, United States and SYDNEY, Australia – 31 July 2014 – GI Dynamics, Inc. (ASX: GID) (GI...

read more

GI Dynamics Announces Departure of Chief Commercial Officer

Company Provides Preliminary Update on Second Quarter Revenues LEXINGTON, MA, United States and SYDNEY, Australia – 1 JULY 2014 – GI Dynamics, Inc. (ASX: GID), a medical device company developing innovative treatments for type 2 diabetes and obesity, announced that Mark C. Twyman is leaving his...

read more

Data Presented at ADA Show the Effects of GI Dynamics’ EndoBarrier® Therapy on Glycemic Control and Reducing Diabetes Medication in Patients with Type 2 Diabetes and Obesity

Data Presented at the Scientific Sessions of the American Diabetes Association Demonstrate Increased Bile Acids Levels Following EndoBarrier Therapy; Further Establishes Potential Mechanism of Action SAN FRANCISCO, United States and SYDNEY, Australia – 16 June 2014 – GI Dynamics, Inc. (ASX: GID),...

read more
Page 10 of 21« First...89101112...20...Last »

Filter By Year